Patents by Inventor Philip Reigan

Philip Reigan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STAT3 transcription factor inhibitors and methods of using the same
    Patent number: 11952353
    Abstract: Compounds that inhibit the activity of Signal transducer and activator of transcription 3 (STAT3), or pharmaceutically acceptable salts or prodrugs thereof, and methods of using these compounds to treat cancer and other diseases.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: April 9, 2024
    Assignee: The Regents of the University of Colorado
    Inventors: Philip Reigan, Donald S. Backos, Christopher J. Matheson, Steffanie L. Furtek, Craig T. Jordan, Maria L. Amaya
  • Fused bicyclic pyrimidine derivatives and uses thereof
    Patent number: 11851436
    Abstract: The present disclosure relates to a compound of Formula (0): a stereoisomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof. The present disclosure also relates to uses of the compound.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: December 26, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Philip Reigan, Kimberly A. Casalvieri
  • FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF
    Publication number: 20230029430
    Abstract: The present disclosure relates to a compound of Formula (0): a stereoisomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof. The present disclosure also relates to uses of the compound.
    Type: Application
    Filed: June 3, 2022
    Publication date: January 26, 2023
    Inventors: Philip REIGAN, Kimberly A. CASALVIERI
  • AMP-ACTIVATED PROTEIN KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20220289707
    Abstract: The present disclosure relates to compounds of Formula (I): stereoisomers thereof, prodrugs thereof, and pharmaceutically acceptable salts thereof. The present disclosure also relates to uses of the compounds, e.g., to inhibit AMP-Activated protein kinase (AMPK) and treat cancer in a subject.
    Type: Application
    Filed: July 2, 2020
    Publication date: September 15, 2022
    Inventors: Philip REIGAN, Christopher J. MATHESON, Craig JORDAN
  • STAT3 TRANSCRIPTION FACTOR INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20220017476
    Abstract: Compounds that inhibit the activity of Signal transducer and activator of transcription 3 (STAT3), or pharmaceutically acceptable salts or prodrugs thereof, and methods of using these compounds to treat cancer and other diseases.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 20, 2022
    Inventors: Philip REIGAN, Donald S. BACKOS, Christopher J. MATHESON, Steffanie L. FURTEK, Craig T. JORDAN, Maria L. AMAYA
  • Wee1 kinase inhibitors and methods of making and using the same
    Patent number: 10947238
    Abstract: A compound, or a pharmaceutically acceptable salt thereof, having a chemical structure of formula (I) or formula (II), and methods of using these compounds to treat cancer in an individual.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: March 16, 2021
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventors: Philip Reigan, Christopher Matheson
  • WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME
    Publication number: 20200405723
    Abstract: A compound, or a pharmaceutically acceptable salts or prodrugs thereof, having the chemical structure: and methods of using these compounds to inhibit WEE1 kinase and treat cancer in a subject.
    Type: Application
    Filed: February 28, 2019
    Publication date: December 31, 2020
    Inventors: Philip REIGAN, Donald S. BACKOS, Christopher J. MATHESON, Kimberly A. CASALVIERI
  • WEE1 KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20190084985
    Abstract: A compound, or a pharmaceutically acceptable salt thereof, having a chemical structure of formula (I) or formula (II), and methods of using these compounds to treat cancer in an individual.
    Type: Application
    Filed: November 1, 2016
    Publication date: March 21, 2019
    Inventors: Philip REIGAN, Christopher MATHESON
  • Indole derivatives and methods of using the same
    Patent number: 10214487
    Abstract: The invention provides indole-4,7-dione derivatives useful for the treatment of diseases in a mammal, pharmaceutical compositions containing the same and methods of using the same in the treatment of cancer and neoplastic diseases including human solid tumors and other mammalian tumors.
    Type: Grant
    Filed: February 27, 2006
    Date of Patent: February 26, 2019
    Assignee: The Regents of the Univeresity of Colorado, a body corporate
    Inventors: David Ross, Philip Reigan, David Siegel, Christopher J. Moody, Marie A. Colucci, Donna Dehn
  • Hsp90 inhibitors, methods of making and uses therefor
    Patent number: 7608611
    Abstract: The invention provides purified 18,21-didehydro-18,21-dideoxo-18,21-dihydroxy-geldanamycin derivatives, pharmaceutically acceptable salts thereof and prodrugs thereof that are potent Hsp90 binding agents that are useful for the treatment and/or the amelioration of symptoms of cancer and other proliferative tissue disorders.
    Type: Grant
    Filed: August 31, 2005
    Date of Patent: October 27, 2009
    Assignee: The Regents of the University of Colorado
    Inventors: David Ross, David Siegel, Philip Reigan, Wenchang Guo, Daniel L. Gustafson
  • INDOLE DERIVATIVES AND METHODS OF USING THE SAME
    Publication number: 20090227652
    Abstract: The invention provides indole-4,7-dione derivatives useful for the treatment of diseases in a mammal, pharmaceutical compositions containing the same and methods of using the same in the treatment of cancer and neoplastic diseases including human solid tumors and other mammalian tumors.
    Type: Application
    Filed: February 27, 2006
    Publication date: September 10, 2009
    Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: David Ross, Philip Reigan, David Siegel, Christopher J. Moody, Marie A. Colucci, Donna Dehn
  • Hsp90 inhibitors, methods of making and uses therefor
    Publication number: 20060205705
    Abstract: The invention provides purified 18,21-didehydro-18,21-dideoxo-18,21-dihydroxy-geldanamycin derivatives, pharmaceutically acceptable salts thereof and prodrugs thereof that are potent Hsp90 binding agents that are useful for the treatment and/or the amelioration of symptoms of cancer and other proliferative tissue disorders.
    Type: Application
    Filed: August 31, 2005
    Publication date: September 14, 2006
    Applicant: University of Colorado
    Inventors: David Ross, David Siegel, Philip Reigan, Wenchang Guo, Daniel Gustafson